Navigation Links
Two-day symposium in Baltimore to tackle the promises and perils of proton radiotherapy
Date:4/3/2009

to surrounding tissues than the broader cone of X-ray photons. This is because the protons penetrate a specific distance into the body and release most of their energy at the very end of this trek via an effect called the Bragg peak.

  • The largest session, chaired by Dr. Christopher Rose of the Valley Radiotherapy Associates Medical Group in California, will take a look the latest clinical studies that test these theoretical advantages in the treatment of cancers of the lungs, skull, and prostate. The technology has proven particularly promising for treating small, shallow cancers near the eyes and spine, and for tumors in children, whose developing organs could be damaged by collateral damage.

  • Speakers in a sister session will argue for a lack of clinical evidence supporting some uses of proton therapy. Evidence that it is superior to older technologies is murky for prostate cancer, for example, a controversy that nevertheless has failed to deter the large number of people currently being treated for prostate cancer.

    "On paper, proton therapy undoubtedly has theoretical advantages but there are many uncertainties involved when we deliver the radiation to the patient," says Dr. Jatinder Palta of University of Florida Health Science Center in Gainesville, who will chair a session considering these difficulties. While better imaging technologies have improved the aiming of proton beams, irregularities in body or the movements of internal organs can still throw off this targeting, causing unintended damage. The consequences of this damage and new schemes to avoid it will be considered.

  • The process of creating proton beams also generates a large number of neutrons -- which may cause secondary cancers. Studies of survivors of the Hiroshima bomb, who received large doses of neutrons, will be presented to assess this risk.

  • Members of the public health community will join in an evidence-based cost-benefit analysis
    '/>"/>

  • Contact: Devin Powell
    dpowell@aip.org
    301-209-3099
    American Institute of Physics
    Source:Eurekalert

    Page: 1 2 3

    Related biology news :

    1. Concerns about food safety to be spotlighted at U of Minnesota symposium
    2. SNM Symposium on Multimodality Cardiovascular Molecular Imaging
    3. Symposium to look at genetic basis of exercise
    4. Public Policy Center hosts flood symposium March 10-12
    5. AAAS Symposium: Emerging threats to tropical, temperate and ocean ecosystems
    6. Symposium at UH will address how to put sustainability into practice
    7. Survival in a Changing World: The Journal of Experimental Biology 2009 symposium
    8. Childrens National convenes first childhood obesity symposium
    9. CTRC-AACR San Antonio Breast Cancer Symposium
    10. The Camille & Henry Dreyfus Foundation to host important symposium on chemistry and the environment
    11. Counter-terrorism symposium held at NJIT tomorrow
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/22/2015)... 2015  BellBrook Labs, a leader in high throughput ... of a TR-FRET (time resolved Forster resonance energy ... a high throughput screening assay for glycosyltransferases and ... for sensitive detection of hundreds of human and ...
    (Date:1/22/2015)... 21, 2015  Analyst Report Issued by Small Cap IR. In ... that planet-wide, transactions at merchants on the leading payment cards ... of credit, debit, and prepaid cards reached 6.54 billion.  Eight ... fraudulent card usage in 2012, and credit and debit card ...
    (Date:1/22/2015)... CHARLOTTE, N.C. , Jan. 22, 2015 Infinisource has ... introduction of the G2 model. The G2 sets a higher ... company,s iSolved human capital management solution. With plug-and-play installation, touch ... G2 time clock provides a robust time collection solution for ...
    Breaking Biology News(10 mins):BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 2Infinisource's NXG series sets new time clock standard 2
    ... the latest American Chemical Society (ACS) News Service Weekly ... Chemical & Engineering News .,Please credit the individual ... for this information. ARTICLE #1 FOR IMMEDIATE RELEASE ... faster with less energy, Chemistry of Materials ...
    ... WHITE PLAIN, N.Y., JULY 27, 2008 In a ... and potentially deadly disorder that affects about 5 percent ... may have important implications for diagnosis and treatment in ... Kellems, Ph.D., Department of Biochemistry and Molecular Biology; and ...
    ... life expectancy for patients with human immunodeficiency virus (HIV) ... late 1990s thanks to advancements in antiretroviral therapy, according ... (UAB) and Simon Fraser University in Vancouver, British Columbia. ... percent drop in AIDS deaths among 43,355 HIV-positive study ...
    Cached Biology News:American Chemical Society's Weekly PressPac -- July 23, 2008 2American Chemical Society's Weekly PressPac -- July 23, 2008 3American Chemical Society's Weekly PressPac -- July 23, 2008 4American Chemical Society's Weekly PressPac -- July 23, 2008 5American Chemical Society's Weekly PressPac -- July 23, 2008 6American Chemical Society's Weekly PressPac -- July 23, 2008 7American Chemical Society's Weekly PressPac -- July 23, 2008 8New research on pre-eclampsia in mice may have important implications for humans 2Anti-HIV therapy boosts life expectancy more than 13 years 2
    (Date:2/27/2015)... , Feb. 27, 2015 A paper ... NCATS rare-diseases portfolio " in Science Translational ... financing technique to reduce the risk associated with ... potentially unlock new levels of funding for developing ... of a unique collaboration between scientists at the ...
    (Date:2/27/2015)... 27, 2015 Immunovaccine Inc. (“Immunovaccine”) ... company, today announced that the U.S. Food and ... Track designation and Phase I clinical trials of ... the mutual co-development agreement signed with Gilead Life ... designation for the DPX-Survivac. , “We have been ...
    (Date:2/27/2015)... , Feb. 27, 2015 Bionomics Limited (ASX:BNO, ... DisrupTOR-1 trial of BNC105 in patients with metastatic renal ... Orlando, Florida . The data will be ... City of Hope Comprehensive Cancer Center in ... The new data identifies Ferritin and IL-8 as ...
    (Date:2/27/2015)... Illinois (PRWEB) February 27, 2015 FamilyFarms ... Sims, General Manager of State Line Farms, received the ... recognizes a producer, under the age of 35, who ... "It is an honor to win the Tomorrow's Top ... discovering who won the Top Producer Award and learning ...
    Breaking Biology Technology:New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 2New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 3New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 4Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 3New BNC105 Biomarker Data to be Presented at US Cancer Conference 2New BNC105 Biomarker Data to be Presented at US Cancer Conference 3New BNC105 Biomarker Data to be Presented at US Cancer Conference 4New BNC105 Biomarker Data to be Presented at US Cancer Conference 5Matt Sims Receives the 2015 Tomorrow’s Top Producer Horizon Award 2
    ... July 26, 2011 The Raymond and ... of Pennsylvania announces the launching of a ... for orphan diseases. The Center will bring together, ... and treating orphan diseases: establishing dedicated research support ...
    ... Fla., July 26, 2011 Dyadic International, Inc. (OTC ... it will report its financial results for the second ... Thursday, August 4, 2011 and will host a conference ... financial results. (Logo: http://photos.prnewswire.com/prnh/20110621/CL06708LOGO) Those ...
    ... CROSS, England, July 26, 2011 , ... one of the,world,s top 20 pharmaceutical companies, is ... with Veeva,CRM in the UK. Daiichi Sankyo will ... in the UK including integrated healthcare,specialty care, medical ...
    Cached Biology Technology:Penn Receives $10 Million to Create Center for Orphan Disease Research and Therapy 2Daiichi Sankyo Selects Veeva CRM to Support Customer Engagement Initiatives in the United Kingdom 2Daiichi Sankyo Selects Veeva CRM to Support Customer Engagement Initiatives in the United Kingdom 3Daiichi Sankyo Selects Veeva CRM to Support Customer Engagement Initiatives in the United Kingdom 4
    ... Lone Wolf valve has the highest performance ... available on the market. This VSO valve ... and ensures maximum accuracy., Achieves rapid, ... and patient comfort. , Maintains ideal flow ...
    Normal Hamster Serum...
    ...
    Hamster Serum; U.S. sourced, ideal for those who seek an uncompromising quality. Low Hemoglobin levels; U.S. sourced, ideal for those who seek an uncompromising quality. Low Hemoglobin levels....
    Biology Products: